End Prescription Drug Ads Now Act

119th Congress Introduced by Maxine Dexter and 2 co-sponsors

HR 4605 bans direct-to-consumer ads for prescription drugs, aiming to improve public health by reducing misleading marketing and promoting informed medication choices.

Introduced in House

Purpose and Intent

The End Prescription Drug Ads Now Act (HR 4605) aims to eliminate direct-to-consumer advertising (DTCA) for prescription drugs in the United States. The primary intent of this legislation is to address concerns regarding the influence of such advertisements on public health, medication adherence, and healthcare costs.

Key Provisions

Ban on DTCA: The bill proposes a complete prohibition on advertisements for prescription drugs directed at consumers. This includes all forms of media, such as television, radio, print, and online platforms.

Regulatory Authority: The bill would grant the Food and Drug Administration (FDA) the authority to enforce this ban and establish penalties for non-compliance.

Public Health Focus: By removing these advertisements, the bill seeks to reduce the pressure on consumers to request specific medications from healthcare providers, potentially leading to more informed and appropriate prescribing practices.

Affected Parties

Pharmaceutical Companies: The primary impact will be on pharmaceutical companies that invest heavily in advertising their products directly to consumers. This could lead to a significant shift in their marketing strategies.

Healthcare Providers: Physicians and healthcare providers may experience changes in patient interactions, as patients may no longer come in with requests for specific medications based on advertisements.

Consumers: The general public may benefit from reduced exposure to potentially misleading drug advertisements, which can lead to better health outcomes and more rational medication use.

Legislative Process and Timeline

Introduced: The bill was introduced in the House of Representatives on July 22, 2025.

Committee Referral: Following its introduction, HR 4605 was referred to the House Committee on Energy and Commerce for further consideration.

Related Legislation: HR 4605 has a companion bill, S 2068, which is currently in the Senate, indicating a broader interest in this legislative initiative.

Conclusion

HR 4605 represents a significant shift in how prescription drugs are marketed to consumers in the United States. By banning direct-to-consumer advertisements, the bill aims to promote public health and ensure that medication decisions are made based on clinical evidence rather than marketing influence. The outcome of this bill could reshape the pharmaceutical advertising landscape and impact various stakeholders in the healthcare system.

Bill